472 related articles for article (PubMed ID: 30112987)
1. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease.
Alkhalil M
Curr Drug Metab; 2019; 20(1):72-82. PubMed ID: 30112987
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
4. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.
Turgeon RD; Pearson GJ
Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110
[TBL] [Abstract][Full Text] [Related]
6. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
Blom DJ; Dent R; Castro RC; Toth PP
Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
[TBL] [Abstract][Full Text] [Related]
8. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
Tziomalos K
Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
[TBL] [Abstract][Full Text] [Related]
9. A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases.
Chen B; Shi X; Cui Y; Hou A; Zhao P
Curr Top Med Chem; 2019; 19(20):1790-1817. PubMed ID: 31400268
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
11. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
[TBL] [Abstract][Full Text] [Related]
12. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
13. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
14. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
15. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
Pirillo A; Catapano AL
Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
Bittner VA; Giugliano RP; Brinton EA; Guyton JR
J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750
[TBL] [Abstract][Full Text] [Related]
17. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
[TBL] [Abstract][Full Text] [Related]
19. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
Liberale L; Montecucco F; Camici GG; Dallegri F; Vecchie A; Carbone F; Bonaventura A
Curr Med Chem; 2017; 24(14):1403-1416. PubMed ID: 28260498
[TBL] [Abstract][Full Text] [Related]
20. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
